论文部分内容阅读
近年来,肿瘤标记物已被用于癌症患者的诊断、治疗监测和预后判断,头颈部鳞癌的肿瘤标记物包括CEA、唾液酸、各种糖蛋白、多胺和免疫复合物,但因其敏感性低而未能在临床上广泛应用。 Cyfra 21-2为非小细胞肺癌新的标记物,Cyfra 21-2即细胞角蛋白片段21-1,它在健康人和良、恶性肿瘤患者中的临床价值已有初步评价,作为肺癌的肿瘤标记物,其敏感性为60％,精确度为95％。作者对250份
In recent years, tumor markers have been used for diagnosis, treatment monitoring and prognosis of cancer patients. The tumor markers of head and neck squamous cell carcinoma include CEA, sialic acid, various glycoproteins, polyamines and immune complexes. Its sensitivity is low and it has not been widely used clinically. Cyfra 21-2 is a new marker for non-small cell lung cancer, Cyfra 21-2, a cytokeratin fragment 21-1. Its clinical value in healthy and benign and malignant tumors has been initially evaluated as a tumor marker for lung cancer. The object has a sensitivity of 60% and an accuracy of 95%. Authors of 250